Does BPC 157 Cause Cancer?

Your body is already running a system that tells blood vessels where to grow, when to grow, and how fast, and BPC-157 plugs directly into that system.

Understanding whether that is a problem requires understanding the whole pathway first.

The system works through something called VEGF, which stands for vascular endothelial growth factor, and it is essentially a chemical signal your body sends out when tissue needs more blood supply. When you tear a muscle or crush a nerve or restrict blood flow to a limb, the damaged cells release VEGF into the surrounding area. That signal travels to nearby blood vessel cells and tells them to divide, migrate, and form new vessels toward the damage. The cells respond because they carry something called VEGFR2 on their surface, which is the receptor that receives the VEGF signal the way an antenna receives a broadcast. More receptors mean a stronger response to the same signal.

BPC-157 works by increasing the number of those VEGFR2 receptors, which makes the whole system more sensitive. A 2017 study using a rat hind limb ischemia model, meaning rats with surgically restricted blood flow, found that BPC-157 activated the VEGFR2-Akt-eNOS signaling pathway and increased vessel density in the ischemic tissue. The peptide did not introduce new signals. It turned up the sensitivity of the receivers so the body's own repair signals landed harder.

That is the mechanism behind the healing. And that is exactly where the cancer question comes from.

Tumors use the VEGF pathway too, and they use it the same way injured tissue does. When a tumor grows beyond a certain size, roughly a few millimeters in diameter, it can no longer get oxygen and nutrients through passive diffusion from nearby vessels. It needs its own blood supply. So it releases VEGF signals into the surrounding tissue and recruits new blood vessels to grow toward it. This process is called angiogenesis, which is the formation of new blood vessels, and it is what allows a small cluster of abnormal cells to become a growing, invasive tumor. Without angiogenesis, most tumors stall out and die.

This is so central to cancer biology that an entire class of drugs, including bevacizumab, was developed specifically to block VEGF and starve tumors of their blood supply.

So the logic of the concern is not paranoid. If BPC-157 upregulates VEGFR2 and amplifies angiogenic signaling, and tumors depend on that same signaling to survive and grow, then it is a reasonable hypothesis that BPC-157 could accelerate tumor progression in someone who already has a tumor growing somewhere in their body, even one too small to detect.

The word there is hypothesis. What the data actually shows is much thinner.

There is one published study testing BPC-157 against cancer cells directly. It was a conference abstract published in 2004 using SK-Mel-1 human melanoma cells in a lab dish. At concentrations of 2 nanograms and 10 nanograms, BPC-157 reduced the total S-phase fraction, which is the proportion of cells actively dividing, by up to 55% compared to controls. That result, if taken at face value, would suggest BPC-157 slows melanoma cell division rather than accelerating it.

But that study has never been independently replicated in over twenty years. It was conducted by researchers affiliated with the same group that has produced most of the BPC-157 literature. It was never published as a full paper. And it tested one cell line, in a dish, which is about as far from a human body as you can get while still technically using human cells.

A 2025 published commentary reviewing the state of BPC-157 research noted that there is no published in vivo data, meaning data from living organisms with actual tumors, demonstrating that BPC-157 inhibits tumor progression, reduces tumor volume, or suppresses metastasis. The same commentary flagged that BPC-157 activates something called FAK-paxillin signaling, which is a pathway associated with cancer cell invasion and migration. That is a different concern than angiogenesis, and it has not been studied in the context of BPC-157 and cancer directly.

The honest summary is this: one unpublished conference abstract suggests a possible inhibitory effect on one melanoma cell line, the mechanism that drives BPC-157's healing effects overlaps significantly with the mechanism tumors use to grow, and no one has studied what happens when you give BPC-157 to a living organism that has an active tumor.

That gap in the literature is not small. It is the entire question.

For someone with no cancer history and no known precancerous conditions, the theoretical risk from BPC-157 appears low based on current data, but current data does not include any direct test of that question in humans or animal tumor models. The absence of evidence of harm is not the same as evidence of absence.

For someone with active cancer, a history of cancer, or known precancerous conditions, the calculus is different. The mechanism is plausible enough, and the data sparse enough, that adding a compound that amplifies angiogenic sensitivity when abnormal cells may already be present is not a risk with a known ceiling. Until well-designed studies in tumor-bearing animal models, and eventually humans, are conducted, that population should not use BPC-157.

The deeper point is about how the body builds things. The same pathway that repairs a torn tendon is the same pathway a tumor hijacks to feed itself. Biology does not have a separate construction crew for healing and a separate one for cancer. It is one crew, getting different orders. BPC-157 does not change the orders. It just makes the crew respond faster to whatever orders are already in the system.

That is why context matters more than the compound itself.

---

References

1. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017;95(3):323-333. Study conditions: Rat hind limb ischemia model and human umbilical vein endothelial cell cultures. Did not test tumor models. Finding: BPC-157 increased VEGFR2 expression and activated the VEGFR2-Akt-eNOS signaling pathway, increasing vessel density in ischemic tissue.
2. Radeljak S, Seiwerth S, et al. BPC 157 inhibits cell growth and VEGF signalling via the MAPK kinase pathway in the human melanoma cell line. Melanoma Research. 2004;14(4):A14-A15 (conference abstract). Study conditions: In vitro, SK-Mel-1 human melanoma cells at 2ng and 10ng concentrations. Authored by Sikiric-affiliated researchers. Never independently replicated. Finding: BPC-157 lowered total S-phase fraction (cell division) up to 55% in SK-Mel-1 melanoma cells compared to controls.
3. Jozwiak M, Bauer M, Kamysz W, Kleczkowska P. Reply to Sikiric et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions. Pharmaceuticals (Basel). 2025;18(10):1451. Published commentary (not original research). Finding: No published in vivo data demonstrate that BPC-157 inhibits tumor progression, reduces tumor volume, or suppresses metastasis. The Radeljak 2004 study remains unreplicated. BPC-157 activates FAK-paxillin signaling, a known pathway in cancer cell invasion.
4. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025;18(12):611-619. Finding: BPC-157 should be considered investigational until well-designed human trials are conducted and published.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness